Ratings by BMO Capital (Etzer Darout)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/7/2025 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Terns Pharmaceuticals | TERN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2025 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2025 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2025 | Q32 Bio Inc. | QTTB | Downgrade | Market Perform (Outperform) |
3.18 (11.16) |
250.94% | Details | |
| 1/29/2025 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2025 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2025 | IGM Biosciences | IGMS | Downgrade | Market Perform (Outperform) |
6.80 (1.27) |
-81.32% | Details | |
| 1/8/2025 | Jasper Therapeutics | JSPR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Exelixis | EXEL | Downgrade | Market Perform (Outperform) |
33.66 (52.87) |
57.07% | Details | |
| 12/12/2024 | Q32 Bio Inc. | QTTB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/6/2024 | Tourmaline Bio | TRML | New Coverage | Outperform (N/A) |
25.59 (47.60) |
86.01% | Details | |
| 12/6/2024 | Q32 Bio Inc. | QTTB | New Coverage | Outperform (N/A) |
24.45 (3.18) |
-86.99% | Details | |
| 12/6/2024 | Nurix | NRIX | New Coverage | Outperform (N/A) |
20.82 (19.30) |
-7.3% | Details | |
| 12/6/2024 | Kymera Therapeutics | KYMR | New Coverage | Market Perform (N/A) |
46.02 (99.87) |
117.01% | Details | |
| 12/5/2024 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
40.58 (122.15) |
201.01% | Details | |
| 12/5/2024 | Jasper Therapeutics | JSPR | New Coverage | Outperform (N/A) |
23.09 (6.77) |
-70.68% | Details | |
| 12/5/2024 | IGM Biosciences | IGMS | New Coverage | Outperform (N/A) |
9.90 (1.27) |
-87.17% | Details | |
| 12/2/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/26/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2024 | Novartis | NVS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Fate Therapeutics | FATE | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/13/2024 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2024 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/7/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2024 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2024 | Novartis | NVS | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/30/2024 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/15/2024 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2024 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2024 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2024 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2024 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2024 | Novartis | NVS | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/20/2024 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2024 | Fate Therapeutics | FATE | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/14/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2024 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/9/2024 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | MacroGenics | MGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/19/2024 | Novartis | NVS | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/24/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/13/2024 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2024 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2024 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2024 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2024 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2024 | Fate Therapeutics | FATE | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/10/2024 | MacroGenics | MGNX | Downgrade | Market Perform (Outperform) |
14.66 (4.78) |
-67.39% | Details | |
| 5/9/2024 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/7/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2024 | Novartis | NVS | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/9/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/5/2024 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2024 | Terns Pharmaceuticals | TERN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/8/2024 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2024 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/29/2024 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2024 | Fate Therapeutics | FATE | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/23/2024 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2024 | Novartis | NVS | New Coverage | Market Perform (N/A) |
102.80 (153.12) |
48.95% | Details | |
| 2/23/2024 | Genmab A/S | GMAB | Upgrade | Outperform (Market Perform) |
29.11 (25.87) |
-11.13% | Details | |
| 2/23/2024 | BioNTech | BNTX | New Coverage | Outperform (N/A) |
93.57 (90.21) |
-3.59% | Details | |
| 2/12/2024 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2023 | Immunogen Inc. | IMGN | Downgrade | Market Perform (Outperform) |
16.06 (31.25) |
94.58% | Details | |
| 11/10/2023 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2023 | Fate Therapeutics | FATE | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/8/2023 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/8/2023 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2023 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2023 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/5/2023 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2023 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2023 | Immunogen Inc. | IMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/10/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2023 | Terns Pharmaceuticals | TERN | New Coverage | Outperform (N/A) |
12.46 (52.95) |
324.96% | Details | |
| 5/8/2023 | Acrivon Therapeutics Inc | ACRV | New Coverage | Outperform (N/A) |
12.53 (1.62) |
-87.07% | Details | |
| 5/3/2023 | Immunogen Inc. | IMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/18/2023 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2023 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2023 | Seagen | SGEN | Downgrade | Market Perform (Outperform) |
172.61 (228.74) |
32.52% | Details | |
| 2/23/2023 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2023 | Seagen | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2023 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2023 | CytomX Therapeutics | CTMX | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/6/2023 | Fate Therapeutics | FATE | Downgrade | Market Perform (Outperform) |
11.12 (2.06) |
-81.47% | Details | |
| 1/5/2023 | AstraZeneca | AZN | New Coverage | Outperform (N/A) |
69.50 (92.77) |
33.48% | Details | |
| 1/5/2023 | Foghorn Therapeutics | FHTX | New Coverage | Outperform (N/A) |
6.53 (4.08) |
-37.52% | Details | |
| 12/20/2022 | Seagen | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Genmab A/S | GMAB | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/20/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2022 | Immunogen Inc. | IMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2022 | CytomX Therapeutics | CTMX | Downgrade | Market Perform (Outperform) |
1.29 (3.32) |
157.36% | Details | |
| 11/14/2022 | MacroGenics | MGNX | Upgrade | Outperform (Market Perform) |
6.73 (4.78) |
-28.97% | Details | |
| 11/11/2022 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Genmab A/S | GMAB | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/8/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | MacroGenics | MGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/31/2022 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2022 | Nuvalent | NUVL | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/11/2022 | Seagen | SGEN | Upgrade | Outperform (Market Perform) |
130.95 (228.74) |
74.68% | Details | |
| 9/12/2022 | Seagen | SGEN | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/11/2022 | Fate Therapeutics | FATE | Upgrade | Outperform (Market Perform) |
30.01 (2.06) |
-93.14% | Details | |
| 7/11/2022 | MacroGenics | MGNX | Downgrade | Market Perform (Outperform) |
3.50 (4.78) |
36.57% | Details | |
| 7/7/2022 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2022 | Seagen | SGEN | New Coverage | Market Perform (N/A) |
169.66 (130.95) |
-22.82% | Details | |
| 6/24/2022 | Genmab A/S | GMAB | New Coverage | Market Perform (N/A) |
30.43 (25.87) |
-14.99% | Details | |
| 6/24/2022 | CytomX Therapeutics | CTMX | New Coverage | Outperform (N/A) |
1.80 (3.32) |
84.44% | Details | |
| 6/24/2022 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
12.01 (123.58) |
928.98% | Details | |
| 6/24/2022 | Y-mAbs Therapeutics | YMAB | New Coverage | Outperform (N/A) |
13.88 (8.61) |
-37.97% | Details | |
| 5/6/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2022 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2022 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
74.68 (8.05) |
-89.22% | Details | |
| 2/11/2022 | C4 Therapeutics | CCCC | New Coverage | Outperform (N/A) |
24.51 (4.25) |
-82.66% | Details | |
| 2/11/2022 | Fate Therapeutics | FATE | New Coverage | Market Perform (N/A) |
40.95 (30.01) |
-26.72% | Details | |
| 2/11/2022 | MacroGenics | MGNX | New Coverage | Outperform (N/A) |
11.76 (3.50) |
-70.24% | Details | |
| 2/11/2022 | Merus N.V. | MRUS | New Coverage | Outperform (N/A) |
26.14 (68.89) |
163.54% | Details | |
| 2/11/2022 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
35.32 (14.45) |
-59.09% | Details | |
| 2/11/2022 | Immunogen Inc. | IMGN | New Coverage | Outperform (N/A) |
6.00 (31.25) |
420.83% | Details |
